Study guide

18.3 Transfusion-Transmitted Diseases

Scientist in Blood Banking, BB ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB

2 Donors and Collection

2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations

3 Processing, Storage, and Component QC

3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control

4 Blood Components

4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors

5 Blood Group Genetics and Transfusion Role

5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence

6 ABO and Lewis Systems

6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System

7 Rh System

7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance

8 Kell, Duffy, Kidd, and MNS

8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System

9 Additional Systems and Antigens

9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens

10 Immunology Foundations

10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties

11 Physiology, Hemostasis, Cytopenias, and Transplantation

11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation

12 Hemolytic Disease of the Fetus and Newborn

12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention

13 Routine Serologic Testing

13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing

14 Antibody Identification

14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps

15 Reagents and Special Techniques

15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods

16 Serologic QA and Special Reagents

16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence

17 Indications and Component Therapy

17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy

18 Adverse Effects of Transfusion

18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases

19 Apheresis, Administration, and Patient Blood Management

19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management

20 Laboratory Operations

20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation

18.3 Transfusion-Transmitted Diseases

Key Takeaways Explain This Topic AI

Residual risk is what remains after donor history and licensed testing — mainly the infectious window period plus untested or undertested agents — not a claim that the blood supply is sterile.

NAT collapsed residual HIV and HCV risk to extremely low levels by shortening the window; do not invent a 1-in-X decimal unless a named current source is in the stem.

The 2026 U.S. allogeneic panel is HIV Ab+NAT, HBV (HBsAg, anti-HBc, NAT), HCV Ab+NAT, HTLV-I/II, syphilis, and WNV NAT each donation; T. cruzi is one-time; Babesia NAT or pathogen reduction applies in 14 endemic states plus D.C.; Zika NAT is not required.

CMV is a special-population problem (CMV-safe = leukoreduced or seronegative). Malaria is travel-deferral, not a routine U.S. donor assay. vCJD remains a theoretical residual risk after most geographic deferrals were removed.

Lookback quarantines remaining components and notifies consignees of prior collections so recipients can be offered testing. Pathogen reduction (licensed for platelets and plasma) is a bacterial and parasite strategy, not a substitute for the HIV/HBV/HCV NAT panel.

Last updated: August 2026

18.3 Transfusion-Transmitted Diseases

Quick Answer: Residual risk is the infection that still sneaks through after history and licensed tests — mainly the window period . NAT made HIV and HCV residual risk extremely low ; do not invent a 1-in-X decimal unless a named current source is in front of you. Current U.S. allogeneic testing is HIV Ab+NAT , HBV (HBsAg, anti-HBc, NAT) , HCV Ab+NAT , HTLV-I/II , syphilis , and WNV NAT on each donation; T. cruzi one-time ; Babesia NAT in endemic regions or pathogen reduction . CMV is a special-population label. Zika NAT is no longer routine . Malaria is travel deferral . vCJD is a theoretical residual . Lookback finds prior recipients. Pathogen reduction addresses bacteria and many parasites in platelets/plasma; it does not retire the viral NAT panel.

This is V.C.3 . Chapter 3.1 already taught the release panel as a manufacturing gate. Chapter 2.1 already taught donor questions, including the shortened malaria travel deferral and the removal of most geographic vCJD deferrals. This section is transfusion practice: what still gets through, whom you protect with extra products, and what you do when a repeat donor later tests reactive.

Residual risk and the window period

No tested inventory is zero-risk. Residual risk is the chance a unit is infectious after donor qualification and licensed screening. The largest named piece for viruses we already test is the window period — the days between infection and the first detectable marker. Antibody tests have long windows. NAT detects viral nucleic acid days to weeks earlier, so the remaining infectious window for HIV and HCV shrank into a very small interval. That is why modern teaching says residual HIV and HCV transfusion risk is extremely low . HBV residual risk remains higher than HIV/HCV even with NAT, because of low-level occult infection and a longer residual window. If an item asks for a specific “1 in …” fraction, it must cite a named current source (FDA, AABB, or a dated national hemovigilance report). This guide will not invent one.

Other residual-risk sources: a testing error , an untested agent (malaria in U.S. allogeneic blood is controlled by history, not a routine licensed NAT), and an agent whose test is one-time or regional ( T. cruzi , Babesia ). Bacterial contamination of platelets is still a quantitative TTD problem compared with HIV; that is why 18.2 and Chapter 4.2 treat bacterial-risk control as part of the product.

Current U.S. allogeneic testing (stay aligned with 3.1)

As of the June 2026 eligibility frame, each allogeneic donation is tested with licensed donor-screening assays for:

  • Agent Assay Cadence
  • HIV Antibody (or Ag/Ab) and NAT Each donation
  • HBV HBsAg, anti-HBc, and NAT Each donation
  • HCV Antibody and NAT Each donation
  • HTLV-I/II Antibody Each donation
  • Syphilis Treponemal or nontreponemal screening test Each donation
  • West Nile virus WNV NAT Each donation
  • Trypanosoma cruzi Antibody One time per donor

Babesia Licensed NAT , or FDA-approved pathogen reduction Year-round in 14 endemic states plus D.C.

Zika virus — Not required (removed as an RTTI, May 2021)

Zika had nationwide NAT after 2016. In May 2021 FDA determined it no longer met the incidence/prevalence bar for an RTTI and withdrew the testing guidance. A 2026 stem that still demands Zika NAT on every U.S. allogeneic unit is using a retired rule, unless it is written as a history item.

Babesia is current. It is an intraerythrocytic parasite that survives 1–6 °C storage , clusters in the Northeast and Upper Midwest , and causes fever, hemolysis, and severe disease in asplenic or immunocompromised recipients. FDA guidance recommends year-round licensed Babesia NAT or an approved pathogen-reduction device for collections in Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia, Wisconsin, and Washington, D.C. Outside those regions, ask the history of babesiosis question; do not pretend refrigeration sterilizes the unit.

T. cruzi (Chagas) is a one-time antibody screen. A nonreactive first test covers later donations from that donor under the FDA-accepted alternative. A reactive result interdicts the current unit and defers the donor. It is not a each-donation NAT.

Platelets still need a bacterial-risk strategy (pathogen reduction, LVDS, or primary-plus-secondary testing). That is TTD prevention, not an optional extra.

CMV, parasites, prions, and what you do not routinely test

CMV is not on the universal allogeneic panel. Most adults are already seropositive. The recipients who need a CMV-safe product are intrauterine transfusions, low-birth-weight neonates, and selected CMV-seronegative immunocompromised patients (including some HPC recipients). CMV-safe means prestorage leukoreduced (residual WBC < 5 × 10^6 ) or CMV-seronegative . Chapter 4.3 already equated leukoreduction with CMV-safe for exam purposes. Ordering both LR and CMV-seronegative is sometimes done for intrauterine work; it is not required for every red-cell issue.

Malaria has no routine U.S. donor laboratory test . Risk is managed by travel and residence deferral (Chapter 2.1 has the current shortened interval). A donor who had clinical malaria is deferred on a longer clock. Do not list malaria NAT next to HIV NAT on a 2026 U.S. panel item.

Other parasites to name: Babesia (above), T. cruzi (above), and, rarely, babesiosis as the clinical disease the recipient actually gets. Tick history in the recipient after a New England red-cell unit is a Babesia lookback trigger, not a Zika story.

Prions / vCJD remain a theoretical residual risk . There is no licensed donor screening test . FDA removed most geographic vCJD deferrals ; do not resurrect a lifetime United Kingdom deferral as if it were still 2010 policy. Leukoreduction is not accepted on the exam as a proven vCJD-prevention strategy that lets you ignore residual theoretical risk.

Lookback and pathogen reduction

Lookback starts when a donor later tests reactive or confirmed-positive , or is implicated in a TTD. The collecting facility quarantines remaining in-date components and notifies consignees of prior collections inside the marker-specific window. HIV lookback is 21 CFR 610.46; HCV lookback is 21 CFR 610.47. Analogous retrieval applies to other markers under FDA guidance and AABB Standards. The transfusion service notifies the recipient’s physician so the recipient can be offered testing and counseling . Destroying only today’s reactive bag and hoping yesterday’s units were already transfused is not compliance.

Worked scenario. A repeat donor is HIV NAT reactive on Monday. Tuesday’s in-date plasma from last month is still in the hospital freezer. Quarantine it. Notify the consignee of earlier donations in the HIV lookback window. Offer recipient testing. Do not wait for a Western blot before freezing movement of in-date co-components.

Pathogen reduction in current U.S. practice is amotosalen plus UVA (INTERCEPT) for platelets and plasma . It is an accepted bacterial-risk strategy , inactivates many viruses and parasites (and is an alternative to Babesia NAT where the device is approved), and contributes to lymphocyte inactivation . It does not replace HIV/HBV/HCV NAT on the collection. It is not a licensed routine red-cell process that lets you skip the red-cell viral panel. Solvent-detergent pooled plasma is a manufacturer-specific pathogen-reduced plasma with its own circular. Fractionated derivatives (albumin, IVIG, RhIG) are pathogen-inactivated during industrial pooling — Chapter 4.4 — and are not a reason to call hospital FFP “sterile.”

  • Problem How U.S. allogeneic blood actually controls it
  • HIV, HCV Antibody plus NAT every donation; residual risk extremely low
  • HBV HBsAg + anti-HBc + NAT every donation
  • HTLV, syphilis, WNV Each-donation serology or NAT as listed
  • T. cruzi One-time antibody
  • Babesia Endemic-region NAT or pathogen reduction
  • Bacteria (platelets) Pathogen reduction or culture/rapid-test strategy
  • CMV Leukoreduced or seronegative for selected recipients
  • Malaria Travel/residence deferral, not a routine assay
  • Zika Not a current required marker
  • vCJD Theoretical residual; most geographic deferrals removed

Exam traps. Do not still require Zika NAT. Do not make Babesia NAT a nationwide every-donation rule. Do not put CMV on the universal panel. Do not invent a residual-risk decimal. Do not say NAT made lookback obsolete. Do not call pathogen-reduced platelets a reason to skip HIV NAT. Do not treat malaria as a laboratory release test.

Loading diagram... Residual TTD risk versus the current U.S. control stack